Clinical trial
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for…
NCT00290511 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00290511 |
|---|---|
| Title | Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma |
| Official title | A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry Biogen |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Fludarabine, Mitoxantrone, Rituximab, Zevalin, Dexamethasone |
| Enrollment | 49 |
| Start date | Jun 29, 2004 |
| Primary completion | Feb 12, 2021 |
| Completion | Feb 12, 2021 |
| First posted | Feb 13, 2006 |
| Last update posted | Apr 22, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: